{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-028352","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2024-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.820305+00:00","generated_at":"2026-05-31T19:42:21.665024+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evofem acquires Solosec from Lupin for up to $84M in contingent consideration","bullets":["Evofem (OTCQB: EVFM) acquired Solosec (secnidazole) from Lupin Inc.; deal closed July 14, 2024.","Potential total consideration up to $84 million based on future contingent milestones; plus assumption of certain liabilities.","Solosec is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.","Acquisition complements Evofem's women's health portfolio, which includes Phexxi; Evofem also in merger with Aditxt (ADTX)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-028352","json":"https://secwatch.observer/filing/0001493152-24-028352.json","markdown":"https://secwatch.observer/filing/0001493152-24-028352.md","text":"https://secwatch.observer/filing/0001493152-24-028352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224028352/0001493152-24-028352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224028352/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:42:21.665024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}